Aminian Keyvan, Farsad Faraneh, Ghanbari Atefeh, Fakhreih Saba, Hasheminasab Sayed Mohammad
Gastrointestinal and Liver Diseases Research Center (GLDRC), Razi Hospital, Tehran, Iran.
Trop Gastroenterol. 2010 Oct-Dec;31(4):303-7.
Helicobacter pylori infection is found in at least 80% of people in developing countries. This randomized controlled trial was performed to evaluate the efficacy of 4 different H. pylori eradication regimens in Iranian patients.
We enrolled 428 patients referred to Razi hospital in Rasht city with dyspepsia. Patients were randomly assigned to four treatment groups of 107 patients (A-D). Group A received omeprazole, amoxicillin, metronidazole and bismuth, all given twice daily for 2 weeks. Group B received omeprazole, amoxicillin and clarithromycin, all given twice daily for 10 days. Group C patients were given omeprazole and amoxicillin, both twice daily for two weeks and ciprofloxacin twice a day for the first week. Group D received 10 days sequential treatment with omeprazole and amoxicillin for 5 days and omeprazole, clarithromycin and metronidazole all twice daily for the remaining 5 days. H. pylori status was rechecked by stool antigen test 8 weeks after treatment. H. pylori eradication rate (both "Intention to Treat" and "per Protocol") and adverse effects of the drugs were recorded after 8 weeks.
Eradication rates in group A to D were, 84.1%, 90.7%, 65.4% and 80.4% respectively in "Intention to Treat" and 85.7%, 90.7%, 70%, and 81.1% respectively in "per Protocol" analyses. Patient compliance was significantly lower in Group C, whereas patient compliance in other groups was not significantly different.
Standard 10 days triple therapy had the highest success (p=0.0001) rate in our study while quadruple therapy was the second successful regimen. Sequential therapy was not found to be an acceptable treatment option.
在发展中国家,至少80%的人感染幽门螺杆菌。本随机对照试验旨在评估4种不同的幽门螺杆菌根除方案对伊朗患者的疗效。
我们招募了428名因消化不良转诊至拉什特市拉齐医院的患者。患者被随机分为4个治疗组,每组107名患者(A - D组)。A组接受奥美拉唑、阿莫西林、甲硝唑和铋剂治疗,均每日2次,持续2周。B组接受奥美拉唑、阿莫西林和克拉霉素治疗,均每日2次,持续10天。C组患者接受奥美拉唑和阿莫西林治疗,均每日2次,持续2周,环丙沙星在第一周每日2次。D组接受序贯治疗,奥美拉唑和阿莫西林治疗5天,随后奥美拉唑、克拉霉素和甲硝唑均每日2次,持续5天。治疗8周后通过粪便抗原检测重新检查幽门螺杆菌感染状况。8周后记录幽门螺杆菌根除率(“意向性治疗”和“符合方案”)以及药物的不良反应。
在“意向性治疗”分析中,A组至D组的根除率分别为84.1%、90.7%、65.4%和80.4%,在“符合方案”分析中分别为85.7%、90.7%、70%和81.1%。C组患者的依从性显著较低,而其他组患者的依从性无显著差异。
在我们的研究中,标准的10天三联疗法成功率最高(p = 0.0001),而四联疗法是第二种成功的方案。序贯疗法未被发现是一种可接受的治疗选择。